Quest Diagnostics Lifts Annual Guidance On Higher COVID-19 Test Revenue Anticipation

  • Quest Diagnostics Inc DGX posted a better-than-expected Q2 FY22 adjusted EPS of $2.36, though down 25.8% Y/Y, beating the consensus of $2.20.
  • Sales came in at $2.45 billion, a decline of 3.8% Y/Y, higher than the Wall Street estimate of $2.34 billion.
  • COVID-19 testing revenues fell 30.5% to $355 million, while Base business revenues improved 2.9% to $2.10 billion.
  • "In Q2, our base business revenues grew year over year while we increased our share of COVID-19 molecular testing thanks largely to our expanded retail relationships," said Jim Davis, CEO-elect.
  • Adjusted operating margin compressed to 17.7% from 22.9% a year ago.
  • Outlook: Quest Diagnostics expects FY22 sales of $9.50 billion - $9.75 billion (prior view $9.2 billion - $9.5 billion), compared to the consensus of $9.42 billion.
  • The company tightened its Base revenue guidance to $8.35 billion - $8.45 billion (prior guidance of $8.35 billion - $8.50 billion).
  • The company anticipates higher COVID-19 testing revenues of $1.15 billion - $1.30 billion (prior forecast of $0.85 billion - $1.0 billion).
  • The company forecasts adjusted EPS of $9.55 - $9.95 compared to the prior guidance of $9.00-$9.50, versus the consensus of $9.33.
  • Price Action: DGX shares are up 0.12% at $135.00 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!